Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene
- 752 Downloads
This review highlights recent epidemiologic, clinical-genetic, and neurochemical advances in our understanding of sporadic amyotrophic lateral sclerosis (ALS) and their relationships to familial ALS caused by superoxide dismutase (SOD1) gene mutations. It is of fundamental importance to recognize that ALS is a biologically heterogeneous syndrome in which genetics, environment, and aging are inter-related. The discovery of mutations in the SOD1 gene is the greatest breakthrough in ALS research since Charcot’s description of the disorder, but the putative toxic gain of function of mutant SOD1 remains elusive despite intense research. Currently, two dominant theories for the pathogenesis of SOD1 mutations exist: specific protein cytotoxicity and protein aggregation. Mutant SOD1 interacts specifically with neurofilament-light chain mRNA and the dynein/dynactin complex, suggesting that cytoskeletal defects and axonal transport are key players. In addition, mutant SOD1 protein has increased propensity to form aggregate-prone monomers, and the degree of instability correlates inversely with length of survival; therefore, increased propensity to aggregate may be the unifying common denominator for the 119 diverse SOD1 mutations.
KeywordsAmyotrophic Lateral Sclerosis Motor Neuron Amyotrophic Lateral Sclerosis Patient SOD1 Gene G93A SOD1 Mouse
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Strong M, Gordon PH: Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum? Amyotroph Lateral Scler Other Motor Neuron Disord 2005, 6:8–16. Excellent review of the difficulties in making differential diagnosis between ALS and other conditions with upper motor neuron pathology.PubMedGoogle Scholar
- 10.Andersen PM, Sims KB, Xin WW, et al.: Sixteen novel mutations in the gene encoding CuZn-superoxide dismutase in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 2:62–73. A large screening study of 2045 ALS patients for SOD1 mutations. A number of patients presented with very atypical features resulting in difficulties in setting the diagnosis. Several patients with SOD1 mutations had been diagnosed as SALS.CrossRefGoogle Scholar
- 33.Turner MR, Hammers A, Al-Chalabi A, et al.: Distinct cerebral lesions in sporadic and ‘D90A’ SOD1 ALS: Studies with [11C]-flumazenil PET. Brain 2005, 128:1323–1329. Flumazenil is a GABA-ligand. Eleven D90A-homozygous patients as well as two D90A-homozygous unaffected relatives were studied. Extensive changes were found in non-motor areas, in particular in the left frontal lobe region. The changes were radically different from the ones observed in 24 patients without SOD1 gene mutations.PubMedCrossRefGoogle Scholar
- 37.Clement AM, Nguyen MD, Roberts EA, et al.: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113–117. Chimeric mice were generated with various proportions of neural and non-neuronal cells with SOD1 mutations. The result is intriguing: it appears that "LMN may be innocent by-standers that are killed by their bad neighbors," but this theory needs confirmation.PubMedCrossRefGoogle Scholar
- 38.Tikka TM, Vartiainen NE, Goldsteins G, et al.: Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neuron disease. Brain 2002, 125:722–731. The authors found that CSF from ALS patients with and without SOD1 mutations had a similar neurotoxic effect to motor neurons in culture, and the effect was blocked by minocycline.PubMedCrossRefGoogle Scholar
- 42.Lindberg MJ, Byström R, BokanÄs N, et al.: Systematically perturbed folding patterns of ALS-associated SOD1 mutants. Proc Natl Acad Sci U S A 2005, 102:9754–9759. The researchers expressed in Escherichia coli the 15 ALSOD mutations from which the best clinical data are available. The purified mutant proteins’ propensity to denaturate and form monomers of stability was analyzed and found to correlate with disease survival time. This is the first time a correlation has been found between protein instability and survival time.PubMedCrossRefGoogle Scholar
- 46.Ge WW, Wen W, Strong W, et al.: Mutant copper-zinc superoxide dismutase binds to and destabilizes human low molecular weight neurofilament mRNA. J Biol Chem 2005, 280:118–124. Private mutations in the neurofilament heavy chain gene had been found earlier in SALS and FALS, but this is the first study to give the neurofilament light chain gene a direct role in ALS pathogenesis. The proposed gain of noxius function is very interesting but needs confirmation on a much larger group of SOD1 mutants, including some of the truncated ones.PubMedGoogle Scholar
- 47.Kieran D, Hafezparast M, Bohnert S, et al.: A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J Cell Biol 2005, 169:561–567. The apriori hypothesis was that the crossbreeding of mice with dynein mutation with G93A SOD1 mice should result in a very aggressive form of murine MND. The opposite result was observed and has been reproduced. This excellent study suggests that active retrograde axonal transport plays a key role in ALSOD pathogenesis.PubMedCrossRefGoogle Scholar
- 51.Puls I, Oh SJ, Sumner CJ, et al.: Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005, 57:687–694. SBMA is an ALS-like disorder without UMN signs. The missense mutation was found to be co-segregated with disease and must be considered to be disease causative.PubMedCrossRefGoogle Scholar
- 52.Münch C, Sedlmeier R, Meyer T, et al.: Point mutation of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004, 63:724–726. The patients studied were two siblings with ALS and two SALS cases. The mutations found have not been proven to be causative, but the balance of evidence points in that direction. What is needed is a large, multigeneration ALS-pedigree where a dynactin mutation co-segregates with the disease+.PubMedGoogle Scholar